Amir Lerman, MD, is Professor of Medicine, Division of Cardiovascular Diseases and Internal Medicine at the Mayo Clinic, Rochester, Minnesota. He serves as the Director of research of the Cardiac Catheterization Laboratory and is Director of the Chest Pain and Coronary Physiology Clinic, and is a Consultant for the Division of Cardiovascular Diseases, Mayo Graduate School of Medicine.
Dr. Lerman graduated with honors from the Technion, Israel Institute of Technology, School of Medicine, in Haifa, Israel.
Dr. Lerman is a Fellow of the American College of Cardiology and the European Society of Cardiology, as well as holding membership in such prestigious organizations as Sigma XI, The Scientific Research Society, the American College of Physicians, Minnesota Medical Association, and the Society of Cardiac Angiography and Interventions, among others. Dr. Lerman is on the editorial boards of several medical journals.
Dr. Lerman has a special interest in the role of the endothelium in vascular tone with emphasis on the coronary circulation in atherosclerosis, acute coronary syndrome, plaque vulnerability, cardiovascular disease in women. His areas of interests also include the clinical approach to the patient with chest pain and non-obstructive disease; coronary physiology and coronary imaging.
Dr. Kahn is the Mary K. Iacocca Professor of Medicine at Harvard Medical School and was formerly the President of the Joslin Diabetes Center. He also has served as Research Director of Joslin for more than 17 years. During his tenure, the Joslin Diabetes Center research program has grown from $2 million to over $25 million, with a staff of over 220 people. Dr. Kahn has received numerous honors and awards, including the highest scientific awards of the American Diabetes Association, Juvenile Diabetes Foundation, International Diabetes Federation, the American Federation of Clinical Research, and the Endocrine Society of the U.S. In 1999, Dr. Kahn received two prestigious national honors — election to membership in the National Academy of Sciences and election to the Institute of Medicine.
Dr. Livingston provides a consulting service (Nick Livingston Consulting, LLC) to biotechnology and pharmaceutical companies on metabolic diseases. He also holds the position of Vice President of Biology for NovaTarg Therapeutics, a company that is developing AMPK activators to treat metabolic disorders and cancer. Before starting his consulting company and joining NovaTarg Therapeutics, he was Vice President at GlaxoSmithKline (GSK) in charge of biology for the Metabolic CEDD, the Center of Excellence in Drug Discovery for diabetes, obesity and the diseases of aging. Prior to joining GSK, Dr. Livingston was Vice President of Metabolic Diseases at Bayer Pharmaceuticals. Here, he was responsible for developing and managing the early discovery programs for type 2 diabetes and obesity. Over his 20 years experience in the pharmaceutical industry, Dr. Livingston has participated in numerous IND applications at Bayer and GSK, writing the preclinical pharmacology sections and reviewing the safety and DMPK sections for products in diabetes, obesity and the diseases of aging. Before joining the pharmaceutical industry, Dr. Livingston had a successful career in academic medicine at the University of Rochester Medical School, attaining the rank of Professor of Medicine, Professor of Pediatrics and Professor of Biochemistry. He has held academic appointments at Yale University School of Medicine and at the Johns Hopkins School of Medicine. Dr. Livingston is the author or co-author of over 90 full-length articles on topics in metabolic diseases.
Frank J. Calzone, Ph.D. has over 22 years of experience in the isolation and preclinical development of protein therapeutics for cancer and other diseases. He is a member of the UCLA Translational Oncology Research Laboratory (TORL) and his research specialties are tumor genomics and drug discovery. He also serves as Vice President of Discovery Research for REMD Biotherapeutics, a company focused on antibody therapies for diabetes and cancer.
Dr. Calzone gained his biotechnology expertise at Amgen. He joined the company as a research scientist in 1993 to identify novel growth factors and cytokines using genomics and transgenic mice. He is an inventor on the Amgen patent that first described osteoprotegerin. His research shifted in 2000 to antibody therapeutics targeting growth factor and cytokine receptors in cancer. He led the team that generated ganitumab, an inhibitory IGF1R antibody, and he served as scientific lead as it advanced clinically. He was a member of the Amgen Ventures SAB, and departed the company as a Scientific Executive Director in 2012.
Dr. Calzone has a long history of public service in breast cancer research and advocacy. He has been a scientific advisor to the Artemis Project of the National Breast Cancer Coalition from the beginning of the program in 2010. He serves on the DOD-CDMRP-BCRP integration panel (2007-present) which has overseen the investment of over $3 billion in breast cancer research.
Dr. Calzone received a Ph.D. in Molecular, Cellular and Developmental Biology from the University of Rochester. He performed his postdoctoral research in developmental biology at Caltech. He was an Assistant Professor (tenure track) at the University of California, Irvine in Developmental and Cell Biology (1989-1993).